EMA launches expert panel pilot programme for breakthrough medical devices — European regulatory pathway accelerating
Summary
The European Medicines Agency (EMA) launched an expert panel pilot programme for breakthrough medical devices in April 2026, as noted in Neurotech Notables #53. The pilot provides neurotech and medtech companies with early scientific advice from multi-disciplinary expert panels on breakthrough medical device clinical development strategies — a European counterpart to the FDA's Breakthrough Device Designation program. The EMA pilot is particularly relevant for European neurotech companies like CorTec (Germany), INBRAIN (Spain), Neurosoft Biosystems, and Salvia BioElectronics who are developing CE mark pathways alongside or instead of US FDA pathways.
Why it matters
An EMA expert panel pilot for breakthrough devices is a structural upgrade to the EU medical technology regulatory environment that neurotech companies have been lobbying for since the MDR transition created CE mark uncertainty in 2021-2023. Early EMA scientific advice on breakthrough device clinical programs prevents the costly trial redesigns that result from regulatory feedback only at submission — the same benefit FDA's TAP program provides for US-focused companies.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial